利妥昔单抗诱导和维持治疗巩膜炎和肉芽肿性多血管炎（韦格纳氏）患者。
Rituximab Induction and Maintenance Treatment in Patients with Scleritis and Granulomatosis with Polyangiitis (Wegener's).
机构信息
a Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham , Massachusetts , USA.
b Ocular Immunology and Uveitis Foundation , Weston , Massachusetts , USA.
出版信息
Ocul Immunol Inflamm. 2018;26(8):1166-1173. doi: 10.1080/09273948.2017.1327602. Epub 2017 Jun 19.
AIMS
To evaluate the efficacy and safety of rituximab (RTX) induction and maintenance treatment for patients with scleritis and granulomatosis with polyangiitis (GPA), Wegener's.
METHODS
Nine patients (12 eyes) with scleritis with GPA who did not respond to corticosteroids and more than one immunosuppressive agent who received ongoing maintenance RTX treatment were identified. Demographics and outcome measures were recorded.
RESULTS
Median follow-up time of 30 months (range, 15 to 87 months). All 12 eyes achieved remission during the RTX maintenance period with a median time in remission of 14 months (range, 5-76 months), and median interval between RTX initiation and inactive disease of 5 months (range, 2-8 months). Two eyes in two patients relapsed. One received steroid eye drops, and the other received a short-term increased dose of intravenous corticosteroids.
CONCLUSIONS
RTX was effective as an induction and maintenance treatment in our small cohort of patients with GPA-associated scleritis.
目的
评估利妥昔单抗（RTX）诱导和维持治疗对巩膜炎和肉芽肿性多血管炎（GPA）、韦格纳的疗效和安全性。
方法
确定了 9 名（12 只眼）对皮质类固醇和一种以上免疫抑制剂反应不佳的 GPA 相关巩膜炎患者，正在接受持续的 RTX 维持治疗。记录了人口统计学和结果测量数据。
结果
中位随访时间为 30 个月（范围 15 至 87 个月）。在 RTX 维持期内，12 只眼全部缓解，缓解中位时间为 14 个月（范围 5-76 个月），RTX 起始与无疾病状态之间的中位间隔为 5 个月（范围 2-8 个月）。两名患者的两只眼睛复发。一只眼接受了皮质类固醇眼药水治疗，另一只眼接受了短期静脉内皮质类固醇剂量增加治疗。
结论
RTX 作为诱导和维持治疗在我们的 GPA 相关巩膜炎小队列患者中是有效的。
Zotero 插件